2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation.

[1]  R. Coffman,et al.  Development of TLR inhibitors for the treatment of autoimmune diseases , 2008, Immunological reviews.

[2]  Jian Huang,et al.  Toll-like receptors in inflammation, infection and cancer. , 2007, International immunopharmacology.

[3]  L. Joosten,et al.  Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. , 2007, Arthritis and rheumatism.

[4]  N. Gay,et al.  Structure and function of Toll receptors and their ligands. , 2007, Annual review of biochemistry.

[5]  B. Beutler,et al.  TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity , 2007, Nature Medicine.

[6]  S. Akira,et al.  Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides , 2006, European journal of immunology.

[7]  H. Cottam,et al.  Synthesis and immunostimulatory activity of 8-substituted amino 9-benzyladenines as potent Toll-like receptor 7 agonists. , 2006, Bioorganic & medicinal chemistry letters.

[8]  W. Sterry,et al.  Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases , 2006, The British journal of dermatology.

[9]  S. H. van der Burg,et al.  Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: towards synthetic epitope-based vaccines. , 2006, Bioorganic & medicinal chemistry letters.

[10]  Tomoaki Nakamura,et al.  Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers. , 2006, Journal of medicinal chemistry.

[11]  Yu-Tseung Liu,et al.  Activation of anti-hepatitis C virus responses via Toll-like receptor 7. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Tomai,et al.  Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 , 2005, The Journal of Immunology.

[13]  A. Kurimoto,et al.  Prodrugs of 9-benzyl-8-hydroxy-2-(2-hydroxyethylthio)adenine: potent interferon inducing agents in monkeys. , 2004, Chemical & pharmaceutical bulletin.

[14]  A. Kurimoto,et al.  Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. , 2004, Bioorganic & medicinal chemistry.

[15]  A. Kurimoto,et al.  Synthesis and structure-activity relationships of 2-amino-8-hydroxyadenines as orally active interferon inducing agents. , 2003, Bioorganic & medicinal chemistry.

[16]  A. Kurimoto,et al.  Synthesis and structure-activity relationships of 2-substituted-8-hydroxyadenine derivatives as orally available interferon inducers without emetic side effects. , 2003, Bioorganic & medicinal chemistry.

[17]  H. Sajiki,et al.  Synthesis and biological evaluation of 2,8-disubstituted 9-benzyladenines: discovery of 8-mercaptoadenines as potent interferon-inducers. , 2003, Bioorganic & medicinal chemistry.

[18]  H. Sajiki,et al.  Efficient synthesis of 2,9-disubstituted 8-hydroxyadenine derivatives. , 2003, Organic & biomolecular chemistry.

[19]  A. Kurimoto,et al.  Discovery of 8-hydroxyadenines as a novel type of interferon inducer. , 2002, Journal of medicinal chemistry.

[20]  S. Akira,et al.  Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.

[21]  N. Strominger,et al.  Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation , 2001, Brain Research Bulletin.

[22]  K. Beutner,et al.  Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. , 1999, Journal of the American Academy of Dermatology.

[23]  D. Reding,et al.  Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. , 1993, Cancer research.

[24]  D. Bernstein,et al.  Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. , 1988, Antiviral research.

[25]  Sun Hee Jin,et al.  Imiquimod, a Toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes. , 2009, The Journal of investigative dermatology.

[26]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.